Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sleeping beauty generated CD19 CAR T-Cell therapy for advanced B-Cell hematological malignancies.
Singh H, Srour SA, Milton DR, McCarty J, Dai C, Gaballa MR, Ammari M, Olivares S, Huls H, De Groot E, Marin D, Petropoulos D, Olson AL, Anderlini P, Im JS, Khouri I, Hosing CM, Rezvani K, Champlin RE, Shpall EJ, Cooper LJN, Kebriaei P. Singh H, et al. Among authors: huls h. Front Immunol. 2022 Nov 10;13:1032397. doi: 10.3389/fimmu.2022.1032397. eCollection 2022. Front Immunol. 2022. PMID: 36439104 Free PMC article. Clinical Trial.
The effects of intranasal esketamine on on-road driving performance in patients with major depressive disorder or persistent depressive disorder.
Dijkstra FM, van de Loo AJ, Abdulahad S, Bosma ER, Hartog M, Huls H, Kuijper DC, de Vries E, Solanki B, Singh J, Aluisio L, Zannikos P, Stuurman FE, Jacobs GE, Verster JC. Dijkstra FM, et al. Among authors: huls h. J Psychopharmacol. 2022 May;36(5):614-625. doi: 10.1177/02698811221078764. Epub 2022 Feb 25. J Psychopharmacol. 2022. PMID: 35212235 Free PMC article. Clinical Trial.
Adoptive immunotherapy with double-bright (CD56bright /CD16bright ) expanded natural killer cells in patients with relapsed or refractory acute myeloid leukaemia: a proof-of-concept study.
Silla L, Valim V, Pezzi A, da Silva M, Wilke I, Nobrega J, Vargas A, Amorin B, Correa B, Zambonato B, Scherer F, Merzoni J, Sekine L, Huls H, Cooper LJ, Paz A, Lee DA. Silla L, et al. Among authors: huls h. Br J Haematol. 2021 Dec;195(5):710-721. doi: 10.1111/bjh.17751. Epub 2021 Sep 7. Br J Haematol. 2021. PMID: 34490616 Clinical Trial.
Long-term outcomes of Sleeping Beauty-generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas.
Srour SA, Singh H, McCarty J, de Groot E, Huls H, Rondon G, Qazilbash M, Ciurea S, Bardelli G, Buck J, Alousi A, Nieto Y, Rezvani K, Marin D, Popat U, Hosing C, Shpall EJ, Wierda WG, Kantarjian H, Champlin RE, Cooper LJ, Kebriaei P. Srour SA, et al. Among authors: huls h. Blood. 2020 Mar 12;135(11):862-865. doi: 10.1182/blood.2019002920. Blood. 2020. PMID: 31961918 Free PMC article. No abstract available.
Development and Validation of the Immune Status Questionnaire (ISQ).
J F Wilod Versprille L, J A E van de Loo A, Mackus M, Arnoldy L, A L Sulzer T, Vermeulen SA, Abdulahad S, Huls H, Baars T, Scholey A, Kraneveld AD, Garssen J, Verster JC. J F Wilod Versprille L, et al. Among authors: huls h. Int J Environ Res Public Health. 2019 Nov 27;16(23):4743. doi: 10.3390/ijerph16234743. Int J Environ Res Public Health. 2019. PMID: 31783555 Free PMC article.
53 results